Recent Updates
Recently added Catalysts

PF-06946860

Phase 1

Cachexia | Monoclonal antibody | Oncology |Pfizer, Inc.|Trials Updated: Jan 12, 2024

PF-06946860 development status

Highest phase Phase 1
Registered trials 4 across 1 sponsor since Jul 2018

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDBiomarker
Total Trials2
Total Enrollment29

FDA Designations

No designations recorded

PF-06946860 clinical trials

PF-06946860 · 2 trials · 11 indications

Phase 1 2
NCT04803305Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and AnorexiaNon-small Cell Lung Cancer
COMPLETED18 Analytics
NCT04299048Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.Cachexia
COMPLETED11 Analytics
PHASE1COMPLETED
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
Non-small Cell Lung CancerUnlock trial analytics
PHASE1COMPLETED
Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.
CachexiaUnlock trial analytics

Study Endpoints

Primary Endpoints

Change From Baseline in Cancer-Related Cachexia Symptom Assessment in Appetite Score at Week 4 in Part A
Baseline, Week 4

The Cancer-Related Cachexia Symptom Assessment-Appetite was a self-reported questionnaire that measured the severity of anorexia. The measure consisted of 1 question that asked study participants to rate their appetite over the past 7 days from 0-"no appetite" to 10-"very good appetite", where higher score indicated better appetite. In this Outcome Measure (OM), changes from baseline in the Cancer-Related Cachexia Symptom Assessment-Appetite score at Week 4 were summarized descriptively by treatment group.

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
From Day 1 up to Week 24

An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) was defined as an AE: 1. resulting in death, 2. was life-threatening, 3. required inpatient hospitalization or prolongation of existing hospitalization, 4. resulted in persistent disability, 5. was a congenital anomaly/birth defect, or considered to be an important medical event. An AE was considered an TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs.

Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
From Day 1 up to Week 24

Participants with laboratory test abnormalities (without regard to baseline abnormality) that met pre-specified criteria included Hemoglobin\< 0.8x lower limit of normal (LLN); Hematocrit\< 0.8x LLN; Erythrocytes (Ery.)\< 0.8x LLN; Ery. Mean Corpuscular Volume\< 0.9x LLN; Leukocytes\< 0.6x LLN; Lymphocytes\< 0.8x LLN; Bilirubin\> 1.5x upper limit of normal (ULN); Aspartate Aminotransferase\> 3.0x ULN; Alkaline Phosphatase\> 3.0x ULN; Protein\< 0.8x LLN; Sodium\< 0.95x LLN; Chloride\< 0.9x LLN; Calcium\< 0.9x LLN; Bicarbonate\< 0.9x LLN; Glucose\> 1.5x ULN; C Reactive Protein\> 1.1x ULN; for urinalysis, Urine Glucose ≥1, Ketones ≥1, Urine Protein ≥1, Urine Hemoglobin ≥1, Urobilinogen ≥1, Nitrite ≥1, and Leukocyte ≥1 Esterase ≥1; Hyaline Casts \>1/LPF.

Number of Participants With Post-Baseline Vital Signs Abnormalities
From Day 1 up to Week 24

Vital signs (pulse rate, systolic and diastolic blood pressure) were obtained with participant in the supine position. The pre-specified categorical analysis criteria in vital signs, were supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg), supine SBP increase/decrease from baseline ≥30 mmHg; supine diastolic blood pressure (DBP) \<50 mmHg, supine DBP increase/decrease from baseline ≥20 mmHg; supine pulse rate \<40 beats per minute (bpm) or \>120 bpm.

Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities
From Day 1 up to Week 24

ECG data (PR interval, QRS interval, QT interval, and QTcF) were obtained with participant in the supine position. The pre-specified categorical analysis criteria in ECG, were PR interval: value ≥300 milliseconds (msec), percentage change ≥25/50%; QRS interval: value ≥140 msec, percentage change ≥50%; QT interval: value ≥500 msec; QTcF interval: 470\< value ≤480 msec, 480\< value ≤500 msec, value \>500 msec, and 30\< change ≤60 msec, change \>60 msec.

Secondary Endpoints

Change From Baseline in Cancer-Related Cachexia Symptom Assessment in Appetite Score at Weeks 1, 2, 3, 5 and 6 in Part A
Baseline, Weeks 1, 2, 3, 5 and 6
Change From Baseline in Cancer-Related Cachexia Symptom Assessment in Fatigue Score at Weeks 1, 2, 3, 4, 5 and 6 in Part A
Baseline, Weeks 1, 2, 3, 4, 5 and 6
Number of Participants With All-Causality Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in Part A
Day 1 through Week 6 (for a period of 6 weeks)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Double-Blind PF-06946860 Treatment followed by Open Label PF-06946860 TreatmentEXPERIMENTALsubcutaneous injection
Double-Blind Placebo Treatment followed by Open-Label PF-06946860 TreatmentPLACEBO_COMPARATORsubcutaneous injection
PF-06946860EXPERIMENTALsubcutaneous injection

Interventions

NameTypeDescription
PF-06946860DRUGsubcutaneous injection
Placebo for PF-06946860DRUGsubcutaneous injection
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites33

Key Inclusion Criteria: * Documented diagnosis of non-small cell lung, pancreatic, colorectal, prostate, breast or ovarian cancer which, in the treating oncologist's assessment, is considered advanced. * Anorexia as defined by a score of ≤5 in the Cancer-Related Cachexia Symptom Assessment Appetite...

Countries:United StatesCanada
Unlock Eligibility Criteria

Frequently asked questions about PF-06946860

What is PF-06946860?

PF-06946860 is an investigational monoclonal antibody developed by Pfizer, Inc. (PFE). It is being studied in Phase 1 clinical development for cachexia in patients with advanced cancer, including non-small cell lung cancer. It is a biomarker-selected therapy, meaning trial enrollment has been guided by a biomarker.

What is PF-06946860 used for in cachexia and non-small cell lung cancer?

PF-06946860 is being studied for cachexia, a wasting syndrome involving loss of appetite, weight, and muscle, in patients with advanced cancer such as non-small cell lung cancer. It has been evaluated in Phase 1 trials that enrolled adults with cancer and cachexia. It is investigational and not approved for any use.

Who makes PF-06946860?

PF-06946860 is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the sponsor of the clinical program evaluating the monoclonal antibody in cancer-related cachexia.

What phase is PF-06946860 in?

PF-06946860 is in Phase 1 clinical development. It is an investigational monoclonal antibody and has not been approved by the FDA for any indication. Its completed Phase 1 studies enrolled small numbers of patients with cancer and cachexia.

What clinical trials is PF-06946860 in?

PF-06946860 has been studied in two completed Phase 1 trials. NCT04803305 compared repeated doses of the investigational drug with placebo and assessed appetite in advanced cancer and anorexia, enrolling 18 patients in the United States and Canada. NCT04299048 assessed safety and tolerability in patients with cancer and cachexia, enrolling 11 patients in the United States.